Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

Lupin Continues Good Run With Agency

The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits. Scrip takes a look at the likely impact.

Ups And Downs For Companies
US FDA's Inspections Have Long Impacted Indian Companies' Earnings • Source: Shutterstock

The US Food and Drug Administration (FDA) has had a significant influence on the direction Indian pharma companies’ revenues could head in a financial year given the dependence of these companies on North America and the role played by the agency as the geography’s gatekeeper.

More from Manufacturing

More from Business